Uli Stilz is Vice President of the Novo Nordisk Bio Innovation Hub in Boston, MA. In this role he is leading a cross functional R&D team establishing innovative partnerships with biotech, venture capital, and academia to co-create novel therapies and technologies to improve the life of patients with cardiometabolic and rare diseases.
Uli graduated with a Master degree in Organic Chemistry from ETH Zürich. He then moved to the Max-Planck-Institute of Biochemistry in Martinsried, where he received his Ph.D. in 1990. After postdoctoral studies at the California Institute of Technology he joined Hoechst AG where he held various positions before he was appointed Associate Vice President of the newly established Innovation unit within the Diabetes Division at Sanofi in 2010. Over a period of 20 years he contributed to more than 60 preclinical and clinical drug candidates
across cardiometabolic, immunology, and oncology therapy areas.
Uli was appointed adjunct professor at the University of Frankfurt in 2012. He serves on various Editorial Boards for international peer-reviewed journals, is member of Scientific Advisory Boards in North America and Europe, and has represented Novo Nordisk A/S at trade organisations (EFPIA). Between 2012 and 2014 he was President of the European Federation for Medicinal Chemistry.
In 2014 he joined Novo Nordisk A/S in Copenhagen, relocated to Boston in 2019, and assumed his current role as Vice President of the Novo Nordisk Bio Innovation Hub in 2020.